The latest round of tariff announcements in the last few days means that by the end of the year, essentially all Chinese goods exported to the U.S. will be subject to duties.China Economyread more
Futures fell after Trump said the U.S. will raise tariffs on more than $500 billion worth of Chinese imports, increasing trade tensions.Marketsread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
Hours after President Trump said Sunday he had "second thoughts" about escalating the trade war with China, the White House sought to explain his remark because it was...Politicsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
Despite Kudlow's expectations, China said on Saturday that it strongly opposes Trump's decision to levy additional tariffs on $550 billion worth of Chinese goods, and warned...Politicsread more
President Donald Trump said Sunday he was not happy after North Korea launched short-range ballistic missiles over the weekend.Politicsread more
Bryn Mawr Trust CIO Jeffrey Mills lists where to put money to work as Wall Street copes with trade war and recession jitters.Futures Nowread more
The announcement for Target also comes on the heels of a strong quarterly earnings report, where it showed it drove more people to stores and got them to spend more money...Retailread more
The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
With a blood test, doctors might someday detect cancer in the earliest stages.
That's the dream of a handful of start-ups in the so-called "liquid biopsy" space. The companies are sequencing DNA from circulating cancer cells in the blood and are raising massive amounts of cash to bring this technology from the lab to medical clinics in the next decade. This type of early-stage screening technology isn't currently available.
Silicon Valley's Guardant Health announced on Thursday that it raised $360 million in a round led by technology conglomerate SoftBank, bringing its total funding to $500 million.
As part of the investment, Guardant announced an ambitious goal to sequence 1 million cancer patients within 5 years.
Guardant has an edge on its competition as it already has a test on the market, targeting patients that have been diagnosed with cancer. Dubbed Guardant360, the test is used by doctors via blood draws to track and monitor how the patient is responding to treatment.
Guardant's funding round is dwarfed by the capital being raised by Grail, a startup that originally spun out of Illumina. Grail is led by former Google executive Jeff Huber, who joined the company after his wife died from cancer. Grail raised just shy of $1 billion, and is still looking for additional strategic investment.
Freenome, a Silicon Valley startup, raised a more modest $65 million from Silicon Valley investment firms, including Andreessen Horowitz and Google Ventures.
The technology is promising, but it's not yet been proven in the real world. These companies will need to collect a large volume of data and conduct extensive clinical trials before reaching patients. The tests will need to be cheap, accurate and sensitive enough to pass muster with doctors and regulators.
"It's now an arms race," said Sabah Oney, a geneticist and business development lead at Alector, a Silicon Valley-based therapeutics company. "It's rapidly becoming a big data problem, and everyone is looking for the silver bullet."